Descriptive analysis of adverse events following immunization with oral cholera vaccine in Lebanon
Bibliographic Data
| ID | 22077338 |
|---|---|
| Authors | Abeer Zeitoun (0000-0002-2720-413X, Ministry of Public Health), Aya Ibrahim (0000-0003-1408-7322, Ministry of Public Health), Sarah Reda El Sayed, Safinaz Sayed (0000-0002-3415-1961, Ministry of Public Health), Eva Hobeika (0000-0002-9618-0004, Holy Spirit University of Kaslik), Rita Karam (0000-0002-7309-3813, Lebanese University, corresponding author) |
| Year | 2024 |
| Volume | 12 |
| Pages | 1480744-1480744 |
| Publication date | 2024-11-20 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2024.1480744 |
| PMID | 39635205 |
| OpenAlex | W4404551650 |
| Language | EN |
| References cited | 22 |
Background: A national Oral Cholera Vaccine (OCV) Euvichol-Plus® campaign was launched in Lebanon, in response to the first outbreak in three decades, recorded in October 2022. The OCV vaccination campaign was carried out between November 2022 and February 2023. This study aims to cover adverse events reports, received at the Lebanese National Pharmacovigilance Program's (LNPVP) passive surveillance system. Methods: test. A descriptive analysis was performed based on age, gender, vaccine administered, and adverse event(s) associated with the administered vaccine. Results: A total of 115 Adverse Events Following Immunization (AEFIs) were reported, which corresponded to 46 case reports. The top three reported AEFIs were fever (39.13%), diarrhea (30.43%), and vomiting (30.43%). Reported cases were non-serious (82.6%). The highest proportion of Individual Case Safety Reports (ICSRs) received is attributed to females (56.5%), and the age category of 2 and 11 years old (41.3%). Reporters' age range was 1-74 years old. Conclusion: Monitoring AEFIs through the cholera outbreak's emergency campaign favors the safety profile of OCV
Adverse effect · Biology · Cholera · Cholera vaccine · Family medicine · Immune system · Immunization · Vaccination · Vibrio cholerae · Influenza Virus Research Studies · Intramuscular injections and effects · Medicine · Vibrio bacteria research studies · Immunology · Pediatrics · Pharmacology · Virology
| Highly cited | No |
|---|